Abstract
Background Atherosclerosis epitomizes a multifaceted cardiovascular disorder, predominantly characterized by the accumulation of cholesterol-laden plaques within arterial walls. Despite substantial research, the precise mechanisms governing the formation of these cholesterol-rich plaques remain partially elucidated. This study delves into the complex interplay of interleukin-6 (IL-6) receptors, shedding light on their pivotal role in orchestrating cholesterol homeostasis in human macrophages.
Methods This investigation evaluated the correlation between interleukin-6 (IL-6), its receptors (IL6R/CD126), and glycoprotein 130 (gp130), alongside established atherosclerosis biomarkers. The cohort comprised 142 subjects, balanced between lean and obese individuals (71 each). Subsequent analyses utilized THP-1-derived macrophages to discern the biochemical repercussions of inhibiting IL-6 receptors on cellular mechanisms.
Results Data indicates a significant upsurge in IL-6 secretion correlating with atherosclerotic manifestations in the obese subset, accompanied by a concomitant diminution in IL-6 receptors IL6R/CD126 and gp130 on circulating monocytes within this group. Pharmacological obstruction of the gp130 receptor in macrophages provoked pronounced alterations in lipid metabolism, notably impacting cholesterol management. These alterations were evidenced by an escalated expression of the LDLR gene, responsible for cholesterol uptake, and a surge in de novo cholesterol synthesis, marked by the upregulation of SREBF2 and its downstream effector, mevalonate kinase (MVK). Concurrently, an increase in HMG-CoA reductase protein levels was observed. Intriguingly, a rise in intracellular cholesterol production coupled with a reduction in ABCA1 levels was noted, suggesting a potential impediment in cholesterol efflux in cells deficient in gp130. This hypothesis was further substantiated by Filipin III staining, which indicated cholesterol retention in cells subjected to gp130 inhibition. Clinical implications of these discoveries were corroborated through experiments on PBMCs from lean participants, where the gp130 inhibitor curtailed cholesterol efflux to levels comparable to those in untreated cells.
Conclusion Collectively, our research underscores the instrumental role of gp130 in the reverse cholesterol transport pathway of macrophages. These insights pave the way for novel therapeutic strategies targeting atherosclerosis and its associated cardiovascular complications, spotlighting gp130 as a potential focal point for intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Kuwait Foundation for the Advancement of Sciences Grant RA CB-2023-017 (FAR.)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the study was secured from the Kuwait Ministry of Health Ethical Board (Approval ID#: 1806/2021) and the Ethical Review Committee (ERC) of the Dasman Diabetes Institute, Kuwait (Approval ID#: RA MoH-2022-002)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author on reasonable request.
